secwatch.observer — SEC 8-K summary
======================================

Issuer:     Evofem Biosciences, Inc. (EVFM)
CIK:        0001618835
Form:       8-K
Filed at:   2023-12-12T23:59:59+00:00
Accession:  0001493152-23-044597
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 1.02, 5.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aditxt to acquire Evofem for ~$100M in stock and debt assumption; expected close H1 2024
--------------------------------------------------------------------------------

- Evofem shareholders to receive 610,000 shares of Aditxt common stock; preferred stock to note, warrant, and preferred holders.
- Aditxt assumes ~$18M in senior secured notes; to pay $5M by year-end 2023, $8M by Sep 2024, plus up to $5M more.
- Termination fee of $4M if Evofem accepts a superior proposal; both boards unanimously approved the deal.
- Evofem posted $13.4M net sales of Phexxi in first 9 months of 2023; non-hormonal birth control market valued at $27.7B in 2022.
- Closing conditions include shareholder approvals, SEC registration effectiveness, and Aditxt regaining Nasdaq compliance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1618835/000149315223044597/0001493152-23-044597-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1618835/000149315223044597/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-044597

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer